雙成藥業(002693.SZ):2024年度預虧5500萬元–8000萬元
格隆匯1月17日丨雙成藥業(002693.SZ)公佈2024年度業績預吿,2024年利潤總額虧損8,000萬元–1,1000萬元,比上年同期下降9.64%-50.75%;歸屬於上市公司股東的淨利潤虧損5,500萬元–8,000萬元,比上年同期下降8.39%-57.66%;扣除非經常性損益後的淨利潤虧損5,837萬元-8,337萬元,比上年同期下降141.79%-245.36%;基本每股收益虧損0.1329元/股–0.1932元/股;營業收入1.5億元-1.9億元,扣除後營業收入1.4億元-1.8億元。
影響利潤變動的主要原因:(1)隨着醫藥行業集採政策的持續推進,納入集採範圍的藥品增多,公司產品進入國家集採後價格下降明顯、未進入集採的產品銷量下滑;(2)公司主要產品注射用胸腺法新上年同期受政策調整的持續影響,銷量較大,而本報吿期無此類因素影響,銷量下降;(3)本報吿期固定資產減值損失、人力成本,研發投入、諮詢鑑證等費用同比增長;(4)本報吿期政府補助收益及理財收益同比減少。
預計報吿期內非經常性損益對淨利潤的貢獻金額為人民幣337萬元左右,主要系政府補助收入及理財收益等。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.